02.10.2015 Views

studies

2015SupplementFULLTEXT

2015SupplementFULLTEXT

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 833A<br />

Disclosures:<br />

The following authors have nothing to disclose: Michael Cheung, She-Yan Wong,<br />

Arun Mathew, Dina Halegoua-De Marzio<br />

1262<br />

Downstaging or Bridging Therapy of Hepatocellular<br />

Cancer Does Not Increase Incidence of Biliary Complications<br />

after Liver Transplantation<br />

Meera Ramanathan 2 , Mark Pedersen 2 , Myunghan Choi 3 , Anil B.<br />

Seetharam 1 ; 1 Banner Transplant and Advanced Liver Disease Center,<br />

University of Arizona College of Medicine-Phoenix, Phoenix,<br />

AZ; 2 Internal Medicine, University of Arizona College of Medicine-Phoenix,<br />

Phoenix, AZ; 3 Arizona State University College of<br />

Nursing and Health Innovation, Phoenix, AZ<br />

Background: Donor and vascular risk factors predisposing to<br />

bile duct ischemia are causes of biliary complications after liver<br />

transplant (LT). Manipulation of the hepatic artery prior to LT as<br />

often occurs in the management of hepatocellular cancer (HCC)<br />

may represent a novel risk factor for non anastomotic biliary<br />

complications. Aim: Evaluate effect of pre-LT hepatic artery<br />

based locoregional therapy on incidence of non anastomotic<br />

biliary complications after LT. Methods: Retrospective cohort<br />

study of consecutive LT recipients between 2009 and 2013.<br />

Incidence of non anastomotic biliary complications (stricture<br />

or leak) tabulated by review of radiologic or endoscopic cholangiogram.<br />

Univariate regression evaluated donor, recipient,<br />

surgical, and locoregional treatment variables associated with<br />

increased risk of biliary complication: cytomegalovirus (CMV)<br />

donor status, organ source (brain or cardiac death), donor<br />

age, native model for end stage liver disease (MELD) and body<br />

mass index (BMI) at LT, etiology of cirrhosis (viral vs. non-viral),<br />

warm ischemic time, cold ischemic time, need for take back surgery<br />

to control bleed in the 1 st month post LT, number of lesions<br />

at the time of HCC diagnosis, modality of arterial locoregional<br />

treatment (chemo vs radio-embolization) and number of treatment<br />

sessions. Variables of interest (p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!